- Sort by Product ID
- Display 30 Products per page
Published: June 1, 2007 | Price: $500.00 – $5,990.00
Multiple sclerosis (MS) is a chronic demyelinating CNS disease that causes significant disability in young adults and others. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life. Kalorama Information's: Multiple Sclerosis Treatments: World Market Outlook to 2011 is one of the few publications to take a detailed look at multiple sclerosis treatment market worldwide, as well as treatments that...Published: June 1, 2007 | Price: $995.00 – $1,990.00
The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, over 1.6 billion people worldwide suffer from tuberculosis, and it is now presenting a major crisis in public health circles. As illustrated by Kenneth G. Krul, Phd., in Kalorama Information's Global Tuberculosis Strategies, there are abundant opportunities for diagnostic and pharmaceutical companies in combating the global tuberculosis threat. As the author details, there are primarily three focal...Published: June 1, 2007 | Price: $1,990.00 – $6,990.00
Toxicity is a crucial parameter that is measured throughout the drug development process. Toxic side-effects are one of the most common reasons drug candidates fail. Toxicity can be a factor of dose, the form in which the drug is administered, and the time of exposure before elimination. Patient responses also differ widely, depending on their age and metabolism and other products in the patient’s system may augment the effect of the drug. Just twenty years ago, toxicology was something that...Published: July 1, 2007 | Price: $5,995.00 – $11,990.00
This series provides total coverage of the Anti-Infectives market, a market that is changing due to product development resistance issues and in some cases, generic competition. Antifungals Antibacterials Antivirals As part of its comprehensive coverage, each report includes: Epidemiology including Incidence Statistics for each type of infection. Current Market Size and Revenue Forecasts for each market segment to assist with long term planning. Discussion of Competitive Products in the market and new products in the delivery pipeline. Coverage of Generic...Published: May 1, 2007 | Price: $2,700.00 – $5,990.00
This third volume of Kalorama Information’s World Market for Anti-Infectives series, the 2nd. Edition focuses on three general product segments of antiviral treatment: Nucleoside Analogs Protease Inhibitors Other Misc. Antivirals The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides: Revenue Data by Infection Type An overview of products on the market Review of products in the development pipeline Market estimates and forecasts through 2011 Market segmentation by geographic region...Published: April 1, 2007 | Price: $4,995.00 – $9,990.00
Novel pharmacological and biological approaches to disease are calling for novel systems of delivering therapies. This has focused attention on the market for drug delivery systems and the pharmaceuticals that are sold along with those technologies. Kalorama's Drug Delivery Systems focuses on these technologies. This offer is for the entire 4 volumes of Kalorama's 2nd edition of its Drug Delivery Markets series, covering all major types, including: Oral Delivery Implantable/Injectable Pulmonary Transdermal/Transmucosal While oral delivery remains the most popular and...Published: April 1, 2007 | Price: $1,295.00 – $2,995.00
SMOKING CESSATION IS AN increasingly important area of focus for pharmaceutical companies, healthcare entities and governments. There are 1.4 billion smokers in the world, and smoking is a known cause of heart disease, lung cancer, respiratory infections and many other diseases. This has created a large market for smoking cessation aids. The market, which Zyban currently holds a tenuous lock on, is about to change, with a major new brand ready to shake up the current market share. At the...Published: April 1, 2007 | Price: $2,495.00 – $4,990.00
New biological treatments are being developed at a record pace, but their potential could be compromised by a significant obstacle: the delivery of these drugs into the body. Pharmaceutical delivery is now nearly as important as product. Kalorama's Drug Delivery Markets Series covers these new systems. The fourth volume of this series, Kalorama's Drug Delivery Markets, Vol. IV: Transdermal and Transmucosal Drug Delivery is a complete overview of a delivery mechanism that offers some advantages: low pain, infection risk, fewer...Published: April 1, 2007 | Price: $2,995.00 – $5,990.00
The market for antibiotics has changed and a knowledge of the current drug resistance situation is critical before operating in this marketplace. The effectiveness of many antibacterials (antibiotics) is being reduced as more and more types of bacteria become resistant to them. These and other developments are covered in Kalorama's Anti-Infectives, World Markets, Vol. II: Antibacterials providing extensive detail on the anti-bacterial market, including the following critical trends: Drug resistance and Interactions Antibiotic Abuse Antibiotic Cycling Addressing Market Trends Antibiotic...Published: March 1, 2007 | Price: $2,495.00 – $4,990.00
The lungs are considered by many to be the best alternative for drugs needing to bypass the gastrointestinal tract. With advancing technology, the practice of utilizing the huge surface area of the lungs to delivery drugs into the blood circulation has been slowly transforming into reality. The pulmonary drug delivery market reached $25.5 billion in 2006 and is expected to experience high steady growth in the next five years. Contributing to growth are new technologies such as dry powder inhalers...Published: March 1, 2007 | Price: $2,500.00 – $5,990.00
Over one billion people suffer from fungal infections worldwide, and this number is growing Though Athlete's foot, dandruff, vaginal yeast infection and fungal nail make up the bulk of these cases, there has been a steady increase in the incidence of more serious infections. This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. The increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy has also been...Published: March 1, 2007 | Price: $3,500.00 – $7,990.00
The market for diabetes-related products is huge and continuing to grow. However, it is not the same market as it was just 3 years ago. New trends in care, new products (both therapeutic and diagnostic), new approaches to long-term complications, and changing public health priorities along with geographic variations are shifting the sands of opportunities in diabetes care. This comprehensive re-evaluation of the major world market for diabetes monitoring and therapeutic products provides in-depth data and analysis including: Detailed epidemiology...Published: February 1, 2007 | Price: $2,995.00 – $4,990.00
Fueled by the promise of needle-free mechanisms for vaccine distribution and other pharmaceutical uses, the implantable/injectable drug delivery market is growing rapidly. The development of better delivery systems in conjunction with the discovery of novel pharmacological compounds will lead to continued growth. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products. The implantable/injectable delivery drug market is a expected to grow to over $12 billion by 2010. Kalorama’s Drug Delivery Markets. Edition...Published: February 1, 2007 | Price: $2,500.00 – $7,990.00
With over 6,160 individual data points reflecting useful market data, Kalorama's Cancer Therapeutics: The Worldwide Market, 2nd Edition is the most comprehensive and recent information available on the five key cancer therapy and treatment markets in a syndicated market research report, including the following areas: Chemotherapy, including -Subcategories Alkylating Agents, Antimetabolites, Cytotoxic Agents, Plant Derivatives -Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodar with Market Share for each Hormone Therapy: -Subcategories include Corticosteroids, Hormone Agonists/Antagonists, Aromatase Inhibitors and SERMS...Published: February 1, 2007 | Price: $3,995.00 – $7,990.00
What are the trends that are fueling a new boom in vaccine production and sales? Why is an industry so commonly associated with children finding an increasing marketplace among adult populations? What makes this class of drugs likely to grow at a faster rate than other pharmaceutical products? These are among the questions answered in Kalorama’s in-depth report, Vaccines: The World Market. With the historic success of vaccines in virtually eliminating diseases such as small pox and polio, and with...Published: January 1, 2007 | Price: $995.00 – $7,000.00
The market for psychotherapeutics drugs is about to change dramatically -- and serious pharmaceutical market watchers will want to be prepared. Kalorama’s Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs: World Market is the most exhaustive guide available to this booming market and the direction it is headed in the next four years. Psychotherapeutics treat conditions classified as abnormal behavior, thoughts and feelings that persist for a determined amount of time causing distress or emotional/physical impairment. Depression, anxiety, psychosis, ADHD and nicotine and...Published: November 1, 2006 | Price: $1,200.00 – $7,000.00
Propelled by advances in molecular biology, the cancer vaccine industry is poised for unprecedented growth. This second edition of Kalorama’s groundbreaking 2003 study completely updates the market data and reviews the technological, clinical, and business trends that have shaped and reshaped this emerging field. Specific segments covered in the report include: Cervical cancer, Colorectal cancer, Lung cancer, Lymphoma, Melanoma, Prostate cancer, and Other cancers for which vaccines are in development. Each market segment provides an overview, descriptions of products available...Published: October 1, 2006 | Price: $3,500.00 – $7,000.00
The global market for prescription respiratory drugs encompasses a wide variety of products that treat both common everyday respiratory illnesses as well as serious chronic conditions such as COPD. Technological developments and improved delivery methods have given many health professionals a wider range of products to treat patients with respiratory diseases and have expanded the market for respiratory pharmaceuticals. This comprehensive study of the market for prescription pharmaceutical products to treat respiratory illness examines six distinct drug segments: Anti-inflammatories, Inhaled...Published: October 1, 2006 | Price: $995.00 – $7,000.00
The orthopedic drug market is a highly competitive market and, in some areas, the competitive environment is being shaped by increasing levels of generic competition. Several large pharmaceutical companies compete in the orthopedic drug market, including Abbott, Eli Lilly, GlaxoSmithKline, Merck, Novartis, and Pfizer among others, and several other suppliers, such as Serono, NovoNordisk, Amgen, and Genentech are developing or offering products in more niche market areas. For the purposes of this study, the world market for orthopedic drugs has...Published: September 1, 2006 | Price: $3,900.00 – $7,800.00
This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. The report contains vital market statistics on three main segments of pharmaceutical contract manufacturing: Biopharmaceutical manufacturing, including monoclonal antibodies (MAbs), complex proteins, peptides, nucleotides, DNA vaccines, and gene therapy. Primary pharmaceutical manufacturing, including non-sterile and sterile active pharmaceutical ingredients (APIs), custom chemicals, certain specialized manufacturing...Published: September 1, 2006 | Price: $1,500.00 – $7,000.00
This report focuses on the applications of current and advanced therapeutics to the treatment of psoriasis and psoriatic arthritis, the options they present, and the progress that is being made in these fields. The major market effects of new therapeutics, with the potential of a breakthrough drug always a possibility, are expected to be seen over the next ten years. The technology trends selected in conjunction with the growing interest in psoriasis and its treatment present the most informative picture...Published: July 1, 2006 | Price: $995.00 – $7,000.00
This report provides and in-depth analysis of the market for prescription drugs used in the treatment of gastrointestinal (GI) disorders, such as nausea and vomiting, heartburn, gastro-esophageal reflux disease (GERD), ulcer, cancers of the GI tract (colorectal, esophageal, and gastric), Crohn’s disease, ulcerative colitis, irritable bowel syndrome (IBS), diverticular disease, constipation, celiac disease, short bowel syndrome, diarrhea, intestinal obstruction, and digestive enzyme disorders. For each major segment, the analysis provides an overview of the diseases including epidemiology, a detailed description...Published: July 1, 2006 | Price: $2,995.00 – $7,800.00
Ophthalmology is entering one of the most remarkable phases in recent history of this industry; new technologies and treatment modalities for both visual acuity and major eye diseases may dramatically change the composition and competitive dynamics of this market. As RK and LASIK changed the market a few years ago, even newer competitive technologies are just now emerging. From the advent of photodynamic therapy and new drug delivery techniques to revolutionary surgical approaches to refractive vision correction, ophthalmology is poised...Published: June 1, 2006 | Price: $995.00 – $7,000.00
Despite troublesome safety problems with past entrants into this market, the veritable epidemic of overweight and obesity continues to make this sector an extremely attractive target for pharmaceutical developers. This new title provides a considered view of the market for medical interventions in the battle against obesity, including U.S. and worldwide market size and growth forecasts, competitive market share and extensive pharmaceutical pipeline information. The report discusses both prescription and OTC drug markets and surgical interventions. Market size and growth...Published: June 1, 2006 | Price: $995.00 – $5,990.00
This report focuses on the specific needs and market applications of the critical care pharmaceuticals market, the options presented by the market, the factors associated with strategic market development, and prospects for the future. The major indications for critical care are discussed as well as the range of pharmaceutical products used in the critical care environment. The strategic market characteristics of the critical care pharmaceuticals market are also discussed. The trends —- cost-containment programs, restricted formulary acceptance, clinical pharmacy, and...Published: May 1, 2006 | Price: $3,500.00 – $7,000.00
CRO is a need-to know practice in pharmaceutical marketing today; but information is not always easy to find. This second edition of Kalorama’s best-selling look at the clinical contract research industry provides the key information competitors need to navigate the complexities and costs of clinical research in the drug development process. In addition to a comprehensive discussion of the market and regulatory environment, the report details: the size and nature of the drug research pipeline, the size and growth of...Published: May 1, 2006 | Price: $3,550.00 – $7,000.00
This complete re-evaluation of the Men’s Health market focuses on the following prescription drug treatment segments: Men’s Cancer Men’s Sexual Dysfunction Men’s Sexually Transmitted Diseases Men’s Urinary Conditions Andropause The report covers drugs used for the treatment of prostate cancer, testicular cancer, impotence, premature ejaculation, and benign prostatic hyperplasia (BPH), urinary incontinence, and STD’s such as HIV, herpes, and genital warts. For each segment, revenues and forecasts are made by type of drug through 2010; competitive market share of the...Published: April 1, 2006 | Price: $2,500.00 – $7,000.00
The landscape of generic companies is changing: their relative might in the industry is increasing and the product lines their offering are growing in depth and breadth. Strong growth in the sector has come not only from more aggressive tactics and better acceptance in the clinical and consumer population, but by the loss of patent protection in the past few years of some huge-name drugs, including Prozac, Zocor, Prilosec, Prevacid, Sporanox, Evista, Flovent, Claritin, Allegra, Diflucan, Zofran, Zoloft, and Pravachol....Published: April 1, 2006 | Price: $3,500.00 – $7,000.00
Adjunctive therapies are not only vital to the success of cancer treatments, enhancing compliance and outcomes, but they are also a dynamic area of research and development in a variety of disciplines from drug delivery to biologics. It also happens to be the largest portion of the overall cancer therapeutics market. This report provides the reader with a comprehensive analysis of the worldwide market for therapeutics to treat and manage symptoms in cancer patients. Market information, including market size and...Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and ethical pressures, geopolitical factors, and evolving marketplace disruptions. For the development of a coherent strategy in this therapeutic area, companies must clearly focus on three...